abstract |
a compound of formula 1 is disclosed as described in the specification and its pharmaceutically acceptable salt. this disclosure also relates to materials and methods for the preparation of the compound of formula 1, to pharmaceutical compositions containing it, and to its use for the treatment of diseases, disorders and conditions associated with gpr6. |